this article describes the acelrx's fiyrtg quarter and Tetraphase acquisition conference call. acelrx is a new institution with a strategic alignment that is a strategic alignment for the hospital pharmaceutical industry. this is an important transaction that provides strategic benefits to both companies. in fact, we entered into a co-promotion agreement whereby both the acelrx and Tetraphase commercial teams will be able to promote each other's products before the merger closes. in addition, we will provide an update on our commercial launch of the disease state - based disease - based disease - based therapy.